Intellia Therapeutics, Inc.
12.21USD
-0.5300 (-4.16%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.79▲ | $-0.79 | 6 | 6 |
| Next quarter | $-0.76▲ | $-0.78 | 7 | 5 |
| Current year | $-3.16▲ | $-3.17 | 8 | 7 |
| Next year | $-2.6▼ | $-1.8 | 5 | 10 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.78 | $-0.8 | -0.02 (-2.0%) |
| 2026-03-31 | $-0.9 | $-0.81 | +0.09 (+9.8%) |
| 2025-12-31 | $-0.96 | $-0.83 | +0.13 (+13.7%) |
| 2025-09-30 | $-0.98 | $-0.92 | +0.06 (+6.6%) |
237 ratings from 39 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Citizens | Reiterated | Market Outperform | $30 | Sep 9, 2026 |
| Wedbush | Maintained | Neutral | $12 $13 | Sep 9, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $25 | Sep 9, 2026 |
| Citizens | Reiterated | Market Outperform | $30 | Aug 25, 2026 |
| Evercore ISI Group | Upgraded from In-Line | Outperform | $16 $24 | Aug 7, 2026 |
| Wolfe Research | Downgraded from Peer Perform | Underperform | $9 | Jul 16, 2026 |
| Wedbush | Maintained | Neutral | $12 $17 | Jul 10, 2026 |
| Canaccord Genuity | Maintained | Buy | $49 | Jun 16, 2026 |
| Citizens | Reiterated | Market Outperform | $30 | Jun 15, 2026 |
| Wedbush | Reiterated | Neutral | $12 | Jun 15, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $25 | Jun 15, 2026 |
| Bernstein | Maintained | Market Perform | $13 $17 | May 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $30 $25 | May 13, 2026 |
| Canaccord Genuity | Maintained | Buy | $58 $49 | May 12, 2026 |
| Wedbush | Reiterated | Neutral | $12 | May 12, 2026 |
| Canaccord Genuity | Maintained | Buy | $48 $58 | Apr 28, 2026 |
| Goldman Sachs | Maintained | Sell | $8 $9 | Apr 28, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $11 $15 | Apr 28, 2026 |
| Citizens | Maintained | Market Outperform | $28 $30 | Apr 28, 2026 |
| Chardan Capital | Maintained | Buy | $27 $30 | Apr 27, 2026 |
| Baird | Maintained | Neutral | $7 $13 | Apr 27, 2026 |
| Jones Trading | Upgraded from Hold | Buy | $29 | Mar 4, 2026 |
| Canaccord Genuity | Maintained | Buy | $54 $48 | Mar 3, 2026 |
| Leerink Partners | Maintained | Outperform | $27 $29 | Mar 3, 2026 |
| RBC Capital | Maintained | Sector Perform | $9 $15 | Mar 3, 2026 |
66 filings from 16 insiders · 7 buy / 4 sell over 6m
Officers and directors of NTLA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| LEONARD JOHN MChief Executive Officer | Sell | 22.7k | $12.60 | $287k | Aug 21, 2026 |
| DULAC EDWARD J IIIChief Financial Officer | Sell | 8.1k | $11.25 | $91k | Jul 22, 2026 |
| DULAC EDWARD J IIIChief Financial Officer | Sell | 4.7k | $18.00 | $84k | Jul 2, 2026 |
| DUBE MICHAEL POfficer | Sell | 2.6k | $16.78 | $44k | Jul 1, 2026 |
| COHEN FREDERICK E. M.D. PH.D.Director | Grant | 9.2k | — | — | Jun 9, 2026 |
| VERWIEL FRANKDirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| CHASE WILLIAM JDirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| GOODMAN JESSEDirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| KERESTY GEORGIADirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| BHANJI MUNADirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| GOFF BRIAN MDirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| CLARK ELIANAChief Technology Officer | Sell | 607 | $13.78 | $8k | Mar 2, 2026 |
| BASTA JAMES EDMUNDGeneral Counsel | Sell | 1.2k | $13.78 | $17k | Mar 2, 2026 |
| LEONARD JOHN MChief Executive Officer | Grant | 156.4k | — | — | Feb 27, 2026 |
| BASTA JAMES EDMUNDGeneral Counsel | Grant | 46.1k | — | — | Feb 27, 2026 |
| LEBWOHL DAVIDOfficer | Grant | 9.9k | — | — | Feb 27, 2026 |
| DULAC EDWARD J IIIChief Financial Officer | Grant | 61.3k | — | — | Feb 27, 2026 |
| CLARK ELIANAChief Technology Officer | Grant | 7.4k | — | — | Feb 27, 2026 |
| DUBE MICHAEL POfficer | Grant | 17.3k | — | — | Feb 27, 2026 |
| SCHULTES BIRGIT C PH.D.Officer | Grant | 39.2k | — | — | Feb 27, 2026 |
No analyst notes on NTLA yet.
Analyst Ratings
17 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 9 | 6 | 2 | 1 | Hold2.63 |
| 1 mo ago | 1 | 9 | 6 | 2 | 1 | Hold2.63 |
| 2 mo ago | 1 | 8 | 7 | 2 | 1 | Hold2.68 |
| 3 mo ago | 2 | 10 | 8 | 1 | 1 | Hold2.50 |